Status:

COMPLETED

A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer

Lead Sponsor:

Affiliated Hospital of Nantong University

Collaborating Sponsors:

The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China

Conditions:

Lung Cancer

Eligibility:

All Genders

18-100 years

Brief Summary

This study aims to explore an optimized treatment regimen of camrelizumab for Chinese patients with non-squamous non-small cell lung cancer. We will evaluate the efficacy, safety, and cost-effectivene...

Detailed Description

1. Evaluate the feasibility, safety, and preliminary efficacy of adding a β-adrenergic receptor blocker to standard anti-PD-1 immunotherapy (camrelizumab). Studies suggest that sympathetic nervous sys...

Eligibility Criteria

Inclusion

  • (1)Histologically confirmed advanced (stage IIIB/IV) NSCLC; (2) Planned to receive first-line anti-PD-1/L1 monotherapy and deemed suitable for such treatment; (3) Older than 18 years of age; (4) ECOG (Eastern Oncology Collaboration group) score 0-1; (5) Ecg and liver and kidney function are normal; (6) No second primary tumor disease or serious complications.

Exclusion

  • (1) Known hypersensitivity to camrelizumab or any of its excipients, or to any component of the planned β-blocker; (2) Clear contraindications to the use of a β-adrenergic receptor blocker; (3)Active infection requiring systemic therapy;(4)Any other concurrent severe illness or clinical condition that, in the investigator's judgment, would interfere with the completion or interpretation of the study protocol or increase patient risk.

Key Trial Info

Start Date :

January 12 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 30 2025

Estimated Enrollment :

59 Patients enrolled

Trial Details

Trial ID

NCT05387512

Start Date

January 12 2022

End Date

November 30 2025

Last Update

January 6 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Pharmacy, Affiliated Hospital of Nantong University

Nantong, Jiangsu, China, 226000

A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer | DecenTrialz